Effects of Ritonavir-Boosted Darunavir,Atazanavir and Lopinavir on Adipose Functions and Insulin Sensitivity in Murine and Human Adipocytes

Abstract

Background

Ritonavir-boosted protease inhibitors (PIs) could adversely affect metabolism and adipose tissue to different extents, depending on the molecule. Using drugs with minimal adverse metabolic effects is an important consideration in at-risk HIV-infected patients. In vitro adipocyte models can be useful for comparing the effects of different PIs.

Methods

We compared the effects of darunavir, darunavir/ritonavir, atazanavir/ritonavir and lopinavir/ritonavir in murine and human adipocytes on differentiation, mitochondrial function, reactive oxygen species (ROS) production and insulin sensitivity.

Results

In human and murine adipocytes, differentiation evaluated by lipid content and protein expression of adipogenic markers, mitochondrial function evaluated by aggregation of the cationic dye JC-1 and by 3-[4,5-dimethyl-thiazol-2-yl]-2,5 diphenyltetrazolium bromide lysis, and mitochondrial mass evaluated by MitoTracker fluorescence and the expression of mitochondrial proteins were unaffected by darunavir, mildly affected by darunavir/ritonavir and further altered by atazanavir/ritonavir and lopinavir/ ritonavir. ROS production was unaltered by darunavir and darunavir/ritonavir but was increased by lopinavir/ritonavir and atazanavir/ritonavir. Regarding insulin sensitivity, darunavir and darunavir/ritonavir had no significant effect on insulin activation of protein kinase B (Akt/PKB) and MAP kinase and of glucose transport, whereas lopinavir/ ritonavir and atazanavir/ritonavir partly impaired the effect of insulin. The effect of atazanavir/ritonavir was generally milder than that of lopinavir/ritonavir.

Conclusions

The various PIs differentially modified adipocyte functions. Darunavir alone did not affect adipocyte functions and only modestly altered differentiation and mitochondrial function when associated with ritonavir. Lopinavir/ritonavir adversely affected differentiation and lipid content, mitochondrial function, ROS production and insulin sensitivity, and the effect of atazanavir/ ritonavir was intermediate. Thus, in vitro, darunavir/ritonavir presented a safer metabolic profile on adipocytes than atazanavir/ritonavir and lopinavir/ritonavir.

References

Lang

, Mary-Krause

, Cotte

Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170: 1228–1238.

Worm

S.W.

, Sabin

, Weber

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201: 318–330.

Mallon

P.W.

Antiretroviral therapy-induced lipid alterations: in-vitro, animal and human studies. Curr Opin HIV AIDS 2007; 2: 282–292.

Noor

M.A.

, Parker

R.A.

, O'Mara

The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004; 18: 2137–2144.

Tomaka

, Lefebvre

, Sekar

Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers. HIV Med 2009; 10: 318–327.

Collot-Teixeira

, De Lorenzo

, Waters

Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression. Clin Pharmacol Ther 2009; 85: 375–378.

Noor

M.A.

, Flint

O.P.

, Maa

J.F.

, Parker

R.A.

Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006; 20: 1813–1821.

Caron-Debarle

, Lagathu

, Boccara

, Vigouroux

, Capeau

HIV-associated lipodystrophy: from fat injury to premature aging. Trends Mol Med 2010; 16: 218–229.

McComsey

, Kitch

, Daar

Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: a prospective, randomized, partially blinded phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infection. 17th Conference on Retroviruses and Opportunistic Infections. 16–19 February 2010, San Francisco, CA, USA. Abstract 106LB.

10.

Valantin

M.A.

, Flandre

, Kolta

Fat tissue distribution changes in HIV-infected patients with viral suppression treated with CDRV/r monotherapy vs 2 NRTI + DRV/r in the MONOI-ANRS 136 randomized trial: results at 48 weeks. 17th Conference on Retroviruses and Opportunistic Infections. 16–19 February 2010, San Francisco, CA, USA. Abstract 721.

11.

Boccara

, Auclair

, Cohen

HIV protease inhibitors activate the adipocyte renin angiotensin system. Antivir Ther 2010; 15: 363–375.

12.

de Jesus

, Ortiz

, Khanlou

Efficacy and safety of darunavir/ritonavir versus lopinavir/ritonavir in ARV-treatment-naive HIV-1-infected patients at week 48: ARTEMIS (TMC114-C211). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. 17–20 September 2007, Chicago, IL, USA. Abstract H718B.

13.

Taburet

A.M.

, Raguin

, Le Tiec

Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clin Pharmacol Ther 2004; 75: 310–323.

14.

Taburet

A.M.

, Piketty

, Chazallon

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48: 2091–2096.

15.

Caron

, Auclair

, Vissian

, Vigouroux

, Capeau

Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues. Antivir Ther 2008; 13: 27–38.

16.

Walker

U.A.

, Auclair

, Lebrecht

Uridine abrogates the adverse effects of antiretroviral pyrimidine analogues on adipose cell functions. Antivir Ther 2006; 11: 25–34.

17.

Leclercq

, Goujard

, Allaert

Prevalence of lipodystrophy among patients on antiretroviral therapy for up to 10 years. A French observational study. Antivir Ther 2010; 15 Suppl 4: A38.

18.

Kim

M.J.

, Leclercq

, Lanoy

A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop Study. Antivir Ther 2007; 12: 1273–1283.

19.

Jemsek

J.G.

, Arathoon

, Arlotti

Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis 2006; 42: 273–280.

20.

Horban

HArribas J, Hill A, van Delft Y, Moecklinghoff C. Anthropometric sub-study of the MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA<50 copies/ml at screening. Antivir Ther 2010; 15 Suppl 4: A36.

21.

Tebas

, Sax

, Aberg

METABOLIK (Metabolic Evaluation in Treatment-naives Assessing the impact of two Boosted protease inhibitors on LIpids and other markers): week 48 comparison of body fat changes in ARV-naive subjects receiving darunavir/ritonavir- or atazanavir/ ritonavir-based therapy. Antivir Ther 2010; 15 Suppl 4: A39.

22.

Lagathu

, Eustace

, Prot

Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther 2007; 12: 489–500.

23.

Jones

S.P.

, Waitt

, Sutton

, Back

D.J.

, Pirmohamed

Effect of atazanavir and ritonavir on the differentiation and adipokine secretion of human subcutaneous and omental preadipocytes. AIDS 2008; 22: 1293–1298.

24.

Hruz

P.W.

, Yan

, Tsai

GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy rodent model system. Antimicrob Agents Chemother 2011; 55: 1377–1382.